UNCLAIMED
Izon Science
Overview
Izon Science, founded in 2005 and based in the United States, operates within the manufacturing sector, specifically focusing on test and measurement equipment. The company specializes in the development of technologies for the separation and analysis of extracellular vesicles (EVs), which are increasingly recognized for their potential in therapeutic and diagnostic applications. Izon has developed the qEV isolation platform, which includes a range of size-exclusion chromatography columns and an Automatic Fraction Collector, to address the challenges associated with large-scale EV separation. Their offerings include the qEV PurePath for Therapeutics, aimed at optimizing EV isolation from cell culture media, and the qEV PurePath for Diagnostics, designed to enhance throughput for isolating EVs from various biofluids. The company’s technical documentation highlights advancements in large-scale EV separation methods, underscoring its commitment to supporting research and industry partners in the growing field of EV applications. With an employee base of 51 to 200 and reported revenue of approximately 17.79 million USD, Izon Science continues to contribute to advancements in this specialized area of research.